Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Selected Grants and Awards

Publications

BAST, RC, BOYER, CM, BERCHUCK, A, XU, FJ, WU, S, LIDOR, Y, MAIER, LA, CREWS, JR, ROSSE, M, VREDENBURGH, JJ, SHPALL, EJ, and PETERS, WP. "NEW STRATEGIES FOR THE MANAGEMENT OF OVARIAN AND BREAST-CANCER BASED ON BIOLOGY AND PHARMACOLOGY." 1992.

Scholars@Duke

Berchuck, A, Boente, MP, Kerns, BJ, Kinney, RB, Soper, JT, Clarke-Pearson, DL, Bast, RC, and Bacus, SS. "Ploidy analysis of epithelial ovarian cancers using image cytometry." Gynecol Oncol 44, no. 1 (January 1992): 61-65.

Scholars@Duke

Xu, FJ, Ramakrishnan, S, Daly, L, Soper, JT, Berchuck, A, Clarke-Pearson, D, and Bast, RC. "Increased serum levels of macrophage colony-stimulating factor in ovarian cancer." Am J Obstet Gynecol 165, no. 5 Pt 1 (November 1991): 1356-1362.

Scholars@Duke

XU, FJ, RAMAKRISHNAN, S, DALY, L, SOPER, JT, BERCHUCK, A, CLARKEPEARSON, D, and BAST, RC. "INCREASED SERUM LEVELS OF MACROPHAGE COLONY-STIMULATING FACTOR IN OVARIAN-CANCER." American Journal of Obstetrics and Gynecology 165, no. 5 (November 1, 1991): 1356-1362. (Academic Article)

Scholars@Duke

Soper, JT, Berchuck, A, and Clarke-Pearson, DL. "Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging." Cancer 68, no. 4 (August 1991): 725-729.

Full Text

Marks, JR, Davidoff, AM, Kerns, BJ, Humphrey, PA, Pence, JC, Dodge, RK, Clarke-Pearson, DL, Iglehart, JD, Bast, RC, and Berchuck, A. "Overexpression and mutation of p53 in epithelial ovarian cancer." Cancer Res 51, no. 11 (June 1, 1991): 2979-2984.

Scholars@Duke

Soper, JT, Couchman, G, Berchuck, A, and Clarke-Pearson, D. "The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma." Gynecol Oncol 41, no. 3 (June 1991): 239-244.

Scholars@Duke

Cliby, W, Soisson, AP, Berchuck, A, and Clarke-Pearson, DL. "Stage I small cell carcinoma of the vulva treated with vulvectomy, lymphadenectomy, and adjuvant chemotherapy." Cancer 67, no. 9 (May 1991): 2415-2417. (Review)

Full Text

Rodriguez, GC, Berchuck, A, Whitaker, RS, Schlossman, D, Clarke-Pearson, DL, and Bast, RC. "Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor." American Journal of Obstetrics and Gynecology 164, no. 3 (March 1991): 745-750.

Full Text

Berchuck, A, Rodriguez, GC, Kamel, A, Dodge, RK, Soper, JT, Clarke-Pearson, DL, and Bast, RC. "Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer." American Journal of Obstetrics and Gynecology 164, no. 2 (February 1991): 669-674.

Full Text

Pages